{"protocolSection":{"identificationModule":{"nctId":"NCT03940742","orgStudyIdInfo":{"id":"17102"},"secondaryIdInfos":[{"id":"I8F-MC-GPGQ","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Tirzepatide in Participants With Impaired Liver Function","officialTitle":"A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment"},"statusModule":{"statusVerifiedDate":"2022-06-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-07-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-22","type":"ACTUAL"},"completionDateStruct":{"date":"2020-09-22","type":"ACTUAL"},"studyFirstSubmitDate":"2019-05-06","studyFirstSubmitQcDate":"2019-05-06","studyFirstPostDateStruct":{"date":"2019-05-07","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-06-09","resultsFirstSubmitQcDate":"2022-06-09","resultsFirstPostDateStruct":{"date":"2023-03-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-06-09","lastUpdatePostDateStruct":{"date":"2023-03-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center."},"conditionsModule":{"conditions":["Hepatic Insufficiency"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":32,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Normal Hepatic Function","type":"ACTIVE_COMPARATOR","description":"Participants with normal hepatic function received single subcutaneous dose of 5 milligrams (mg) tirzepatide.","interventionNames":["Drug: Tirzepatide"]},{"label":"Mild Hepatic Impairment","type":"EXPERIMENTAL","description":"Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.","interventionNames":["Drug: Tirzepatide"]},{"label":"Moderate Hepatic Impairment","type":"EXPERIMENTAL","description":"Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.","interventionNames":["Drug: Tirzepatide"]},{"label":"Severe Hepatic Impairment","type":"EXPERIMENTAL","description":"Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.","interventionNames":["Drug: Tirzepatide"]}],"interventions":[{"type":"DRUG","name":"Tirzepatide","description":"Administered SC","armGroupLabels":["Mild Hepatic Impairment","Moderate Hepatic Impairment","Normal Hepatic Function","Severe Hepatic Impairment"],"otherNames":["LY3298176"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide","description":"Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\\[0-∞\\]) of Tirzepatide.","timeFrame":"Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose"},{"measure":"PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide","description":"PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide.","timeFrame":"Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAll Participants:\n\n* Women of childbearing potential are excluded from the study.\n* Women not of childbearing potential may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or postmenopausal\n* Are between the body mass index (BMI) of 19.0 and 40.0 kilograms per meter squared (kg/m²), inclusive, at screening\n\nHealthy Participants:\n\n\\- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal liver function\n\nParticipants with Impaired Liver Function:\n\n* Males or females with chronic mild, moderate and severe liver impairment, assessed by Child-Pugh scoring\n* Have type 2 diabetes mellitus (T2DM) controlled with diet or exercise alone or on stable doses of metformin for at least 8 weeks\n* Have a hemoglobin A1c (HbA1c) ≥6.0% and ≤11.0% at screening\n\nExclusion Criteria:\n\nAll Participants:\n\n* Have known allergies to tirzepatide or related compounds\n* Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2\n* Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors\n\nParticipants with Impaired Liver Function:\n\n* Have hemoglobin \\<8.5 grams per deciliter (g/dL)\n* Have kidney function that is significantly impaired at screening\n* Have taken any glucose-lowering medications other than metformin, including insulin, in the past 3 months before screening\n* Have brain function impaired significantly due to liver condition","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Orange County Research Center","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"Orlando Clinical Research Center","city":"Orlando","state":"Florida","zip":"32809","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"New Orleans Center for Clinical Research","city":"New Orleans","state":"Louisiana","zip":"70112","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}}]},"referencesModule":{"references":[{"pmid":"35674880","type":"DERIVED","citation":"Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2022 Jul;61(7):1057-1067. doi: 10.1007/s40262-022-01140-3. Epub 2022 Jun 8."}],"seeAlsoLinks":[{"label":"A Study of Tirzepatide in Participants With Impaired Liver Function","url":"https://trials.lillytrialguide.com/en-US/trial/3Q0iEn37gojINvezSaoRkX"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Control (Normal Hepatic Function)","description":"Participants with normal hepatic function received single subcutaneous dose of 5 mg tirzepatide."},{"id":"FG001","title":"Mild Hepatic Impairment","description":"Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"FG002","title":"Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"FG003","title":"Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants.","groups":[{"id":"BG000","title":"Control (Normal Hepatic Function)","description":"Participants with normal hepatic function received single subcutaneous dose of 5 mg tirzepatide."},{"id":"BG001","title":"Mild Hepatic Impairment","description":"Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"BG002","title":"Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"BG003","title":"Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"32"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.8","spread":"11.3"},{"groupId":"BG001","value":"63.2","spread":"4.5"},{"groupId":"BG002","value":"51.3","spread":"15.4"},{"groupId":"BG003","value":"60.4","spread":"6.6"},{"groupId":"BG004","value":"57.4","spread":"10.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"8"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"24"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"28"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"28"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"32"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide","description":"Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\\[0-∞\\]) of Tirzepatide.","populationDescription":"All participants who received at least one dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram*hour per milliliter (ng*h/mL)","timeFrame":"Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose","groups":[{"id":"OG000","title":"Control (Normal Hepatic Function)","description":"Participants with normal hepatic function received single subcutaneous dose of 5 mg tirzepatide."},{"id":"OG001","title":"Mild Hepatic Impairment","description":"Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"OG002","title":"Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"OG003","title":"Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84300","spread":"28"},{"groupId":"OG001","value":"102000","spread":"16"},{"groupId":"OG002","value":"82000","spread":"29"},{"groupId":"OG003","value":"77000","spread":"33"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Ratio of geometric least squares mean","paramValue":"1.08","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.879","ciUpperLimit":"1.32"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Ratio of geometric least squares mean","paramValue":"0.960","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.790","ciUpperLimit":"1.17"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"Ratio of geometric least squares mean","paramValue":"0.852","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.699","ciUpperLimit":"1.04"}]},{"type":"PRIMARY","title":"PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide","description":"PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide.","populationDescription":"All participants who received at least one dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose","groups":[{"id":"OG000","title":"Control (Normal Hepatic Function)","description":"Participants with normal hepatic function received single subcutaneous dose of 5 mg tirzepatide."},{"id":"OG001","title":"Mild Hepatic Impairment","description":"Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"OG002","title":"Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."},{"id":"OG003","title":"Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"510","spread":"28"},{"groupId":"OG001","value":"509","spread":"18"},{"groupId":"OG002","value":"516","spread":"44"},{"groupId":"OG003","value":"521","spread":"23"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Ratio of geometric least squares mean","paramValue":"0.916","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.726","ciUpperLimit":"1.16"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Ratio of geometric least squares mean","paramValue":"1.00","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.802","ciUpperLimit":"1.25"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"Ratio of geometric least squares mean","paramValue":"0.972","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.784","ciUpperLimit":"1.21"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline to Study Completion (Up to 14 Months)","description":"All participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Control (Normal Hepatic Function)","description":"Participants with normal hepatic function received single subcutaneous dose of 5 mg tirzepatide.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":4,"otherNumAtRisk":13},{"id":"EG001","title":"Mild Hepatic Impairment","description":"Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":2,"otherNumAtRisk":6},{"id":"EG002","title":"Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":2,"otherNumAtRisk":6},{"id":"EG003","title":"Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":1,"seriousNumAtRisk":7,"otherNumAffected":2,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Hepatic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-07-18","uploadDate":"2021-08-05T01:23","filename":"Prot_000.pdf","size":6336679},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-05-20","uploadDate":"2021-08-05T01:21","filename":"SAP_001.pdf","size":1855409}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D048550","term":"Hepatic Insufficiency"}],"ancestors":[{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000098860","term":"Tirzepatide"}],"ancestors":[{"id":"D000067757","term":"Glucagon-Like Peptide-1 Receptor"},{"id":"D000067756","term":"Glucagon-Like Peptide Receptors"},{"id":"D043562","term":"Receptors, G-Protein-Coupled"},{"id":"D011956","term":"Receptors, Cell Surface"},{"id":"D008565","term":"Membrane Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D011964","term":"Receptors, Gastrointestinal Hormone"},{"id":"D018000","term":"Receptors, Peptide"}]}},"hasResults":true}